Purpose To provide insight into the current use and results
of ultrasound-facilitated catheter-directed thrombolysis
(USAT) in patients with high-risk pulmonary embolism
(PE).
Introduction Systemic thrombolysis is an effective treatment for hemodynamically unstable, high-risk PE, but is
associated with bleeding complications. USAT is thought
to reduce bleeding and is therefore advocated in patients
with high-risk PE and contraindications for systemic
thrombolysis.
Methods We conducted a retrospective cohort study of all
patients who underwent USAT for high-risk PE in the
Netherlands from 2010 to 2017. Characteristics and outcomes were analyzed. Primary outcomes were major
(including intracranial and fatal) bleeding and all-cause
mortality after 1 month. Secondary outcomes were allcause mortality and recurrent venous thromboembolism
within 3 months.
Results 33 patients underwent USAT for high-risk PE.
Major bleeding occurred in 12 patients (36%, 95% CI
22–53), including 1 intracranial and 3 fatal bleeding. Allcause mortality after 1 month was 48% (16/33, 95% CI
31–66). All-cause mortality after 3 months was 50% (16/
32, 95% CI 34–66), recurrent venous thromboembolism
occurred in 1 patient (1/32, 3%, 95% CI 1–16).
Conclusions This study was the first to describe characteristics and outcomes after USAT in a study population of
patients with high-risk PE only, an understudied population. Although USAT is considered a relatively safe
treatment option, our results illustrate that at least caution
is needed in critically ill patients with high-risk PE. Further
research in patients with high-risk PE is warranted to guide
patient selection